Topic:
Chutes and Ladders
Latest Headlines
Latest Headlines
Jazz CFO joins Medivation's board of directors
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Layoffs, check. Now, on to hiring--and talent's scarce
More than half of pharma's top executives say it's more difficult to recruit the right people these days, according to a new report from PricewaterhouseCoopers.
Juventas snaps up business development veteran
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Novartis welcomes ex-COO as chairman
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Novartis' Jimenez says no need to sell Roche stake
With a new chairman selected to take the helm of Novartis, lots of folks are wondering what is in store for the Swiss drugmaker. Not so fast, CEO Joe Jimenez said this week.
Novartis brings ex-COO home to replace Vasella as chairman
Novartis Chief Joe Jimenez knew the company would reveal that Chairman Daniel Vasella was bowing out--and that his former colleague--and competitor--Joerg Reinhardt would step into the job.
AstraZeneca rejiggers top executive crew
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
MedImmune unit split 3 ways in AstraZeneca shake-up
When the AstraZeneca elevated MedImmune's Bahija Jallal to head up biologics development, it gutted the unit's commercial and manufacturing operations.
AstraZeneca shakeup leaves R&D chief on top of restructured MedImmune
The big shakeup under way at AstraZeneca under new CEO Pascal Soriot has hit home at MedImmune. Peter Greenleaf is out as president of the Gaithersburg, MD-based biotech division and Bahija Jallal, now a member of an R&D troika on AstraZeneca's executive group in the wake of Martin Mackay's ouster, is stepping up to the top spot.
With FDA nod on Uceris, Santarus puts out 'help wanted' sign for sales reps
Now that Santarus ($SNTS) has FDA approval in hand for its ulcerative colitis remedy Uceris, the company plans to staff up on the sales side.
